128 related articles for article (PubMed ID: 21463347)
1. Methotrexate intoxication: the Pharmaceutical Care process reveals a critical error.
Arnet I; Bernhardt V; Hersberger KE
J Clin Pharm Ther; 2012 Apr; 37(2):242-4. PubMed ID: 21463347
[TBL] [Abstract][Full Text] [Related]
2. Adherence to national recommendations for safe methotrexate dispensing in community pharmacies.
Koster ES; Walgers JC; van Grinsven MC; Winters NA; Bouvy ML
J Manag Care Pharm; 2014 Feb; 20(2):194-200. PubMed ID: 24456321
[TBL] [Abstract][Full Text] [Related]
3. Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis.
Bookstaver PB; Norris L; Rudisill C; DeWitt T; Aziz S; Fant J
Am J Health Syst Pharm; 2008 Nov; 65(22):2117-21. PubMed ID: 18997139
[TBL] [Abstract][Full Text] [Related]
4. Short-term methotrexate therapy in psoriasis: a study of 197 patients.
Kumar B; Saraswat A; Kaur I
Int J Dermatol; 2002 Jul; 41(7):444-8. PubMed ID: 12121564
[TBL] [Abstract][Full Text] [Related]
5. Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate.
van Dooren-Greebe RJ; Kuijpers AL; Termorshuizen F; van de Kerkhof PC
Acta Derm Venereol; 1995 Sep; 75(5):393-6. PubMed ID: 8615062
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
Dogra S; Krishna V; Kanwar AJ
Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytopenia after a single test dose of methotrexate.
Jih DM; Werth VP
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 2):349-51. PubMed ID: 9703150
[TBL] [Abstract][Full Text] [Related]
8. [Information transmission to the community pharmacist after a patient's discharge from the hospital: setting up of a written medication discharge form, prospective evaluation of its impact, and survey of the information needs of the pharmacists].
Claeys C; Dufrasne M; De Vriese C; Nève J; Tulkens PM; Spinewine A
J Pharm Belg; 2015 Mar; (1):42-54. PubMed ID: 26571796
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy.
Khopkar U; Bhor U
Indian J Dermatol Venereol Leprol; 2008; 74(4):379-82. PubMed ID: 18797063
[TBL] [Abstract][Full Text] [Related]
10. A Case of Inappropriate Self-Medication Compounded with Prescribing
Roy SS; Roy A; Santra Dhali R; Bagchi C; Banerjee G; Tripathi SK
Curr Drug Saf; 2018; 13(1):51-54. PubMed ID: 28933275
[TBL] [Abstract][Full Text] [Related]
11. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
12. [Apparent worsening of psoriasis lesions revealing methotrexate overdosage].
Haber R; Baroudjian B; Battistella M; Bagot M; Petit A
Ann Dermatol Venereol; 2018 Feb; 145(2):104-108. PubMed ID: 28917574
[TBL] [Abstract][Full Text] [Related]
13. Adverse consequences of low-dose methotrexate medication errors: data from French poison control and pharmacovigilance centers.
Vial T; Patat AM; Boels D; Castellan D; Villa A; Theophile H; Torrents R; Kassai B
Joint Bone Spine; 2019 May; 86(3):351-355. PubMed ID: 30243781
[TBL] [Abstract][Full Text] [Related]
14. Design of the POINT study: Pharmacotherapy Optimisation through Integration of a Non-dispensing pharmacist in a primary care Team (POINT).
Hazen AC; Sloeserwij VM; Zwart DL; de Bont AA; Bouvy ML; de Gier JJ; de Wit NJ; Leendertse AJ
BMC Fam Pract; 2015 Jul; 16():76. PubMed ID: 26135582
[TBL] [Abstract][Full Text] [Related]
15. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal.
Boffa MJ; Chalmers RJ; Haboubi NY; Shomaf M; Mitchell DM
Br J Dermatol; 1995 Nov; 133(5):774-8. PubMed ID: 8555032
[TBL] [Abstract][Full Text] [Related]
16. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema.
Weatherhead SC; Wahie S; Reynolds NJ; Meggitt SJ
Br J Dermatol; 2007 Feb; 156(2):346-51. PubMed ID: 17223876
[TBL] [Abstract][Full Text] [Related]
17. Impact of community pharmacist-performed post-discharge medication reviews in transitions of care.
Tetuan CE; Guthrie KD; Stoner SC; May JR; Hartwig DM; Liu Y
J Am Pharm Assoc (2003); 2018; 58(6):659-666. PubMed ID: 30056133
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
19. More than skin deep.
Riquelme-Mc Loughlin C; Giavedoni P; Mascaró JM
Am J Emerg Med; 2018 Sep; 36(9):1719.e3-1719.e4. PubMed ID: 29861373
[TBL] [Abstract][Full Text] [Related]
20. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
